https://aijourn.com/spruce-biosciences-announces-integrated-long-term-clinical-data-of-tralesinidase-alfa-enzyme-replacement-therapy-ta-ert-demonstrating-profound-and-durable-efficacy-and-safety-in-patients-with-sanfil/
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme...
Aug 14, 2025 - SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTCQB: SPRB), a late-stage biopharmaceutical company focused on developing and
long term